Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: Sustained release of a local antiinflammatory therapeutic

Arthritis and Rheumatism

Volumn 56, Issue 11, 2007, Pages 3650-3661

  Shamji, Mohammed F ^a   Betre, Helawe ^a   Kraus, Virginia B ^b   Chen, Jun ^a   Chilkoti, Ashutosh ^a   Pichika, Rajeswari ^c   Masuda, Koichi ^c   Setton, Lori A ^b,d  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Duke University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; ELASTIN; HYBRID PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN ADAMTS 4; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; ESCHERICHIA COLI; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTERVERTEBRAL DISK; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; RECEPTOR AFFINITY; SURFACE PLASMON RESONANCE; SUSTAINED DRUG RELEASE; THYMOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL DIVISION; CHONDROCYTES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ELASTIN; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERVERTEBRAL DISK; LYMPHOCYTES; MICE; MICE, INBRED C57BL; PEPTIDES; RECEPTORS, INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; TEMPERATURE; THYMUS GLAND; U937 CELLS;

EID: 36049027097     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22952     Document Type: Article

References (44)

1. Pujol JP, Loyau G. Interleukin-1 and osteoarthritis. Life Sci 1987;41:1187-98.
2. Attur MG, Patel IR, Patel RN, Abramson SB, Amin AR. Autocrine production of IL-1β by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians 1998;110: 65-72.
3. Melchiorri C, Meliconi R, Frizziero L, Silvestri T, Pulsatelli L, Mazzetti I, et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998;41: 2165-74.
4. Hopkins SJ, Humphreys M, Jayson MI. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 1988;72:422-7.
5. Abramson SB, Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev 2006;58: 212-25.
6. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999;4: D694-703.
7. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988;82:2026-37.
8. Martel-Pelletier J, Zafarullah M, Kodama S, Pelletier JP. In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage. J Rheumatol Suppl 1991;27:80-4.
9. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets [review]. Arthritis Rheum 2001;44: 1237-47.
10. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990;85:1694-7.
11. Kobayashi M, Squires GR, Mousa A, Tanzer M, Zukor DJ, Antoniou J, et al. Role of interleukin-1 and tumor necrosis factor α in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005;52:128-35.
12. Nuki G, Bresnihan B, Bear MB, McCabe D, for the European Group of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46: 2838-46.
13. McEvoy G. AHFS Drug Information 2006. Bethesda: American Society of Health-System Pharmacists; 2006.
14. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996;39: 1535-44.
15. Chevalier X, Giraudeau B, Conrozier T, Marlierc J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:1317-23.
16. Fernandes J, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999;154: 1159-69.
17. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997;40:1012-9.
18. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 2005;102:8698-703.
19. Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther 2004;11:379-89.
20. Urry DW. Physical chemistry of biological free energy transduction as demonstrated by elastic protein-based polymers. J Phys Chem B 1997;101:11007-28.
21. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA. A thermally responsive biopolymer for intra-articular drug delivery. J Control Release 2006;115:175-82.
22. Meyer DE, Shin BC, Kong GA, Dewhirst MW, Chilkoti A. Drug targeting using thermally responsive polymers and local hyperthermia. J Control Release 2001;74:213-24.
23. Meyer DE, Chilkoti A. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol 1999;17:1112-5.
24. Dreher MR, Raucher D, Balu N, Michael Colvin O, Ludeman SM, Chilkoti A. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J Control Release 2003;91:31-43.
25. Bidwell GL III, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005;4:1076-85.
26. Liu JC, Heilshorn SC, Tirrell DA. Comparative cell response to artificial extracellular matrix proteins containing the RGD and CS5 cell-binding domains. Biomacromolecules 2004;5:497-504.
27. Chow DC, Dreher MR, Trabbic-Carlson K, Chilkoti A. Ultra-high expression of a thermally responsive recombinant fusion protein in E. coli. Biotechnol Prog 2006;22:638-46.
28. Urry DW, Parker TM, Reid MC, Gowda DC. Biocompatibility of the bioelastic materials, Poly(GVGVP) and its γ-irradiation crosslinked matrix: summary of generic biological test results. J Bioact Compat Polym 1991;6:263-82.
29. McPherson DT, Xu J, Urry DW. Product purification by reversible phase transition following Escherichia coli expression of genes encoding up to 251 repeats of the elastomeric pentapeptide GVGVP. Protein Expr Purif 1996;7:51-7.
30. Meyer DE, Chilkoti A. Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. Biomacromolecules 2002;3: 357-67.
31. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-6.
32. Haskill S, Martin G, Van Le L, Morris J, Peace A, Bigler CF, et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci U S A 1991;88:3681-5.
33. Malyak M, Guthridge JM, Hance KR, Dower SK, Freed JH, Arend WP. Characterization of a low molecular weight isoform of IL-1 receptor antagonist. J Immunol 1998;161:1997-2003.
34. Steinkasserer A, Solari R, Mott HR, Aplin RT, Robinson CC, Willis AC, et al. Human interleukin-1 receptor antagonist: high yield expression in E. coli and examination of cysteine residues. FEBS Lett 1992;310:63-5.
35. Daniell H, Guda C, McPherson DT, Zhang X, Xu J, Urry DW. Hyperexpression of a synthetic protein-based polymer gene. Methods Mol Biol 1997;63:359-71.
36. Meyer DE, Trabbic-Carlson K, Chilkoti A. Protein purification by fusion with an environmentally responsive elastin-like polypeptide: effect of polypeptide length on the purification of thioredoxin. Biotechnol Prog 2001;17:720-8.
37. Gill S, von Hippel P. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989;182:319-26.
38. Thompson JP, Pearce RH, Schechter MT, Adams ME, Tsang IK, Bishop PB. Preliminary evaluation of a scheme for grading the gross morphology of the human intervertebral disc. Spine 1990;15: 411-5.
39. Trabbic-Carlson K, Meyer DE, Liu L, Piervincenzi R, Nath N, LaBean T, et al. Effect of protein fusion on the transition temperature of an environmentally responsive elastin-like polypeptide: a role for surface hydrophobicity? Protein Eng Des Sel 2004;17:57-66.
40. Trabbic-Carlson K, Liu L, Kim B, Chilkoti A. Expression and purification of recombinant proteins from Escherichia coli: comparison of an elastin-like polypeptide fusion with an oligohistidine fusion. Protein Sci 2004;13:3274-84.
41. Mecham RP, Hinek A, Griffin GL, Senior RM, Liotta LA. The elastin receptor shows structural and functional similarities to the 67-kDa tumor cell laminin receptor. J Biol Chem 1989;264: 16652-7.
42. Ong SR, Trabbic-Carlson KA, Nettles DL, Lim DW, Chilkoti A, Setton LA. Epitope tagging for tracking elastin-like polypeptides. Biomaterials 2006;27:1930-5.
43. Poole AR, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis 2002;61 Suppl 2:ii78-81.
44. Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM. Gene deletion of either interleukin-1β, interleukin-1β-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 2003;48:3452-63.